ベッカー型筋ジストロフィー治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Becker Muscular Dystrophy - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0811
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年2月28日
◆ページ数:75
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Becker Muscular Dystrophy – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Becker Muscular Dystrophy – Pipeline Review, H1 2020, provides an overview of the Becker Muscular Dystrophy (Genetic Disorders) pipeline landscape.

Becker muscular dystrophy (BMD) is one of type of muscular dystrophy, a group of genetic, degenerative diseases primarily affecting voluntary muscles. Symptoms include pain and sensation, difficulty with running, hopping, and jumping, toe walking, breathing problems, cognitive problems and frequent falls.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Becker Muscular Dystrophy – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Becker Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Becker Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 2 and 4 respectively.

Becker Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Becker Muscular Dystrophy (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Becker Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Becker Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Becker Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Becker Muscular Dystrophy (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Becker Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Becker Muscular Dystrophy – Overview
Becker Muscular Dystrophy – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Becker Muscular Dystrophy – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Becker Muscular Dystrophy – Companies Involved in Therapeutics Development
Armgo Pharma Inc
Catabasis Pharmaceuticals Inc
Edgewise Therapeutics
Epirium Bio Inc
Italfarmaco SpA
Milo Biotechnology LLC
PTC Therapeutics Inc
ReveraGen BioPharma Inc
Sarcomed AB
Tivorsan Pharmaceuticals Inc
Becker Muscular Dystrophy – Drug Profiles
ARM-210 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ataluren – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
edasalonexent – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EDG-001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epicatechin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene therapy To Activate Follistatin For Duchenne Muscular Dystrophy, Becker Muscular Dystrophy And Inclusion Body Myositis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
givinostat – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nandrolone decanoate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TVN-102 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vamorolone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Becker Muscular Dystrophy – Dormant Projects
Becker Muscular Dystrophy – Discontinued Products
Becker Muscular Dystrophy – Product Development Milestones
Featured News & Press Releases
Feb 10, 2016: Catabasis Pharmaceuticals Will Present CAT-1004, a Potential Disease-Modifying Agent in Development for the Treatment of Duchenne Muscular Dystrophy, at the XIV International Conference on Duchenne and Becker Muscular Dystrophy
Jun 30, 2015: Cardero Therapeutics Presents at 2015 Parent Project Muscular Dystrophy Connect Conference
Mar 31, 2015: Cardero Therapeutics Presents at 2015 Muscular Dystrophy Association Scientific Conference
Sep 30, 2014: Becker Trial completed at UC-Davis on the Cardero Therapeutics lead compound
May 31, 2013: Becker Trial initiated at UC-Davis on the Cardero Therapeutics lead compound
Mar 31, 2013: Completed triglyceride trial with Cardero Therapeutics lead compound
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Becker Muscular Dystrophy, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Becker Muscular Dystrophy - Pipeline by Armgo Pharma Inc, H1 2020
Becker Muscular Dystrophy - Pipeline by Catabasis Pharmaceuticals Inc, H1 2020
Becker Muscular Dystrophy - Pipeline by Edgewise Therapeutics, H1 2020
Becker Muscular Dystrophy - Pipeline by Epirium Bio Inc, H1 2020
Becker Muscular Dystrophy - Pipeline by Italfarmaco SpA, H1 2020
Becker Muscular Dystrophy - Pipeline by Milo Biotechnology LLC, H1 2020
Becker Muscular Dystrophy - Pipeline by PTC Therapeutics Inc, H1 2020
Becker Muscular Dystrophy - Pipeline by ReveraGen BioPharma Inc, H1 2020
Becker Muscular Dystrophy - Pipeline by Sarcomed AB, H1 2020
Becker Muscular Dystrophy - Pipeline by Tivorsan Pharmaceuticals Inc, H1 2020
Becker Muscular Dystrophy - Dormant Projects, H1 2020
Becker Muscular Dystrophy - Discontinued Products, H1 2020

【掲載企業】

Armgo Pharma Inc
Catabasis Pharmaceuticals Inc
Edgewise Therapeutics
Epirium Bio Inc
Italfarmaco SpA
Milo Biotechnology LLC
PTC Therapeutics Inc
ReveraGen BioPharma Inc
Sarcomed AB
Tivorsan Pharmaceuticals Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ベッカー型筋ジストロフィー治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆